Is Europe's HAE Market Big Enough To Sustain All The Competitors?
Executive Summary
As more companies of all sizes embrace rare diseases – lured in part by supposed lower regulatory and reimbursement hurdles – some niche markets are beginning to look rather busy.
You may also be interested in...
The First Shall Be Fifth: Salix’s Recombinant C1 Esterase Inhibitor Enters Crowded HAE Market
Ruconest must compete with four other HAE therapies approved by FDA since 2008, including a pair of human plasma-derived C1 esterase inhibitors.
Shire To Test Convenience Versus Familiarity In HAE With Approval Of Firazyr
FDA’s Aug 25 approval of Shire PLC’s Firazyr (icatibant) for acute treatment of attacks of hereditary angioedema, with a label that allows patients to self-administer the drug, puts a convenience advantage up against a first-to-market advantage for the well-established C-1 esterase inhibitors.
Shire To Test Convenience Versus Familiarity In HAE With Approval Of Firazyr
FDA’s Aug 25 approval of Shire PLC’s Firazyr (icatibant) for acute treatment of attacks of hereditary angioedema, with a label that allows patients to self-administer the drug, puts a convenience advantage up against a first-to-market advantage for the well-established C-1 esterase inhibitors.